The janus face of PAMAM dendrimers used to potentially cure nonenzymatic modifications of biomacromolecules in metabolic disorders - A critical review of the pros and cons

Molecules

Volumn 18, Issue 11, 2013, Pages 13769-13811

  Labieniec Watala, Magdalena ^a   Karolczak, Kamil ^b   Siewiera, Karolina ^b   Watala, Cezary ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bioenergetics; Diabetes mellitus; Diabetic markers; Hyperglycaemia; In vivo study; Mitochondria function; Non enzymatic glycosylation; PAMAM dendrimers

Indexed keywords

ANTIDIABETIC AGENT; DENDRIMER; PAMAM STARBURST;

ANIMAL; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; REVIEW;

ANIMALS; DENDRIMERS; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS;

EID: 84888632497     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules181113769     Document Type: Review

References (113)

1. Tomalia, D.A.; Baker, J.R.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. New class of polymers: STARBURST-dendritic macromolecules. Polymer J. 1984, 17, 117-132.
2. Cheng, Y.Y.; Wu, Q.L.; Li, Y.W.; Hu, J.J.; Xu, T.W. New Insights into the Interactions between Dendrimers and Surfactants: 2 Design of New Drug Formulations Based on Dendrimer- Surfactant Aggregates. J. Phys. Chem. B 2009, 113, 8339-8346.
3. Tatiya, P.D.; Hedaoo, R.K.; Mahulikar, P.P.; Gite, V.V. Novel Polyurea Microcapsules Using Dendritic Functional Monomer: Synthesis, Characterization, and Its Use in Self-healing and Anticorrosive Polyurethane Coatings. Ind. Eng. Chem. Res. 2013, 52, 1562-1570.
4. Labieniec, M.; Watala, C. PAMAM dendrimers - diverse biomedical applications. Facts and unresolved questions. Cent. Eur. J. Biol. 2009, 4, 434-451.
5. Labieniec, M.; Ulicna, O.; Vancova, O.; Glowacki, R.; Sebekova, K.; Bald, E.; Gabryelak, T.; Watala, C. PAMAM G4 dendrimers lower high glucose but do not improve reduced survival in diabetic rats. Int. J. Pharm. 2008, 364, 142-149.
6. Labieniec, M.; Ulicna, O.; Vancova, O.; Kucharska, J.; Gabryelak, T.; Watala, C. Effect of poly(amido)amine (PAMAM) G4 dendrimer on heart and liver mitochondria in an animal model of diabetes. Cell Biol. Int. 2009, 34, 89-97.
7. Labieniec, M.; Watala, C. Use of poly(amido)amine dendrimers in prevention of early non-enzymatic modifications of biomacromolecules. Biochimie 2010, 92, 1296-1305.
8. Duncan, R.; Vicent, M.J. Polymer therapeutics-prospects for 21st century: The end of the beginning. Adv. Drug Deliv. Rev. 2013, 65, 60-70.
9. Lazniewska, J.; Milowska, K.; Gabryelak, T. Dendrimersurevolutionary drugs for infectious diseases. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol. 2012, 4, 469-491.
10. Niederhafner, P.; Sebestik, J.; Jezek, J. Glycopeptide dendrimers. Part I. J. Pept. Sci. 2008, 14, 2-43.
11. Shi, X.Y.; Majoros, I.J.; Baker, J.R. Capillary electrophoresis of poly(amidoamine) dendrimers: From simple derivatives to complex multifunctional medical nanodevices. Mol. Pharm. 2005, 2, 278-294.
12. Tomalia, D.A. Birth of a new macromolecular architecture: Dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Aldrichimica Acta 2004, 37, 39-57.
13. Aoi, K.; Itoh, K.; Okada, M. Globular Carbohydrate Macromolecule Sugar Balls.1. Synthesis of Novel Sugar-Persubstituted Poly(Amido Amine) Dendrimers. Macromolecules 1995, 28, 5391-5393.
14. Sebastik, J.; Niederhafner, P.; Jezek, J. Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications. Amino Acids 2011, 40, 301-370.
15. Heiden, T.C.K.; Dengler, E.; Kao, W.J.; Heideman, W.; Peterson, R.E. Developmental toxicity of low generation PAMAM dendrimers in zebrafish. Toxicol. Appl. Pharmacol. 2007, 225, 70-79.
16. Malik, N.; Wiwattanapatapee, R.; Klopsch, R.; Lorenz, K.; Frey, H.; Weener, J.W.; Meijer, E.W.; Paulus, W.; Duncan, R. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Release 2000, 65, 133-148.
17. Neerman, M.F.; Zhang, W.; Parrish, A.R.; Simanek, E.E. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int. J. Pharm. 2004, 281, 129-132.
18. Roberts, J.C.; Bhalgat, M.K.; Zera, R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 1996, 30, 53-65.
19. Karolczak, K.; Rozalska, S.; Wieczorek, M.; Labieniec-Watala, M.; Watala, C. Poly(amido)amine dendrimers generation 4.0 (PAMAM G4) reduce blood hyperglycaemia and restore impaired blood-brain barrier permeability in streptozotocin diabetes in rats. Int. J. Pharm. 2012, 436, 508-518.
20. Karolczak, K.; Kamysz, W.; Karafova, A.; Drzewoski, J.; Watala, C. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: A randomized multicenter study. Pharmacol. Res. 2013, 74C, 7-22.
21. Siewiera, K.; Labieniec-Watala, M. Ambiguous effect of dendrimer PAMAM G3 on rat heart respiration in a model of an experimental diabetes - Objective causes of laboratory misfortune or unpredictable G3 activity? Int. J. Pharm. 2012, 430, 258-265.
22. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 457-481.
23. Peterson, A.V., Jr. Expressing the Kaplan-Meier estimator as a function of empirical subsurvival functions. J. Am. Stat. Assoc 1977, 72, 854-858.
24. Gupta, U.; Agashe, H.B.; Asthana, A.; Jain, N.K. A review of in vitro-in vivo investigations on dendrimers: The novel nanoscopic drug carriers. Nanomedicine 2006, 2, 66-73.
25. Okuda, T.; Kawakami, S.; Maeie, T.; Niidome, T.; Yamashita, F.; Hashida, M. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. J. Control. Release 2006, 114, 69-77.
26. Ambade, A.V.; Savariar, E.N.; Thayumanavan, S. Dendrimeric micelles for controlled drug release and targeted delivery. Mol. Pharm. 2005, 2, 264-272.
27. Wijagkanalan, W.; Kawakami, S.; Hashida, M. Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations. Pharm. Res. 2011, 28, 1500-1519.
28. Aillon, K.L.; Xie, Y.; El Gendy, N.; Berkland, C.J.; Forrest, M.L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Deliv. Rev. 2009, 61, 457-466.
29. Albertazzi, L.; Gherardini, L.; Brondi, M.; Sulis, S.S.; Bifone, A.; Pizzorusso, T.; Ratto, G.M.; Bardi, G. In Vivo Distribution and Toxicity of PAMAM Dendrimers in the Central Nervous System Depend on Their Surface Chemistry. Mol. Pharm. 2013, 10, 249-260.
30. Biricova, V.; Laznickova, A. Dendrimers: Analytical characterization and applications. Bioorg. Chem. 2009, 37, 185-192.
31. Chen, H.T.; Neerman, M.F.; Parrish, A.R.; Simanek, E.E. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 2004, 126, 10044-10048.
32. Thiagarajan, G.; Greish, K.; Ghandehari, H. Charge affects the oral toxicity of poly(amidoamine) dendrimers. Eur. J. Pharm. Biopharm. 2013, 84, 330-334.
33. Wiwattanapatapee, R.; Carreno-Gomez, B.; Malik, N.; Duncan, R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: A potential oral delivery system? Pharm. Res. 2000, 17, 991-998.
34. Florence, A.T.; Sakthivel, T.; Toth, I. Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J. Control. Release 2000, 65, 253-259.
35. Tripathi, P.K.; Khopade, A.J.; Nagaich, S.; Shrivastava, S.; Jain, S.; Jain, N.K. Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie 2002, 57, 261-264.
36. Lee, J.H.; Cha, K.E.; Kim, M.S.; Hong, H.W.; Chung, D.J.; Ryu, G.; Myung, H. Nanosized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicol. Lett. 2009, 190, 202-207.
37. Mukherjee, S.P.; Byrne, H.J. Polyamidoamine dendrimer nanoparticle cytotoxicity, oxidative stress, caspase activation and inflammatory response: Experimental observation and numerical simulation. Nanomedicine 2013, 9, 202-211.
38. Naha, P.C.; Byrne, H.J. Generation of intracellular reactive oxygen species and genotoxicity effect to exposure of nanosized polyamidoamine (PAMAM) dendrimers in PLHC-1 cells in vitro. Aquat. Toxicol. 2013, 132-133, 61-72.
39. Thomas, T.P.; Majoros, I.; Kotlyar, A.; Mullen, D.; Holl, M.M.; Baker, J.R., Jr. Cationic poly(amidoamine) dendrimer induces lysosomal apoptotic pathway at therapeutically relevant concentrations. Biomacromolecules 2009, 10, 3207-3214.
40. Labieniec, M.; Gabryelak, T. Preliminary biological evaluation of poli(amidoamine) (PAMAM) dendrimer G3.5 on selected parameters of rat liver mitochondria. Mitochondrion 2008, 8, 305-312.
41. Mukherjee, S.P.; Lyng, F.M.; Garcia, A.; Davoren, M.; Byrne, H.J. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells. Toxicol. Appl. Pharmacol. 2010, 248, 259-268.
42. Nyitrai, G.; Kekesi, O.; Pal, I.; Keglevich, P.; Csiki, Z.; Fugedi, P.; Simon, A.; Fitos, I.; Nemeth, K.; Visy, J.; Tarkanyi, G.; Kardos, J. Assessing toxicity of polyamidoamine dendrimers by neuronal signaling functions. Nanotoxicology 2012, 6, 576-586.
43. Labieniec-Watala, M.; Siewiera, K.; Jozwiak, Z. Resorcylidene Aminoguanidine (RAG) Improves Cardiac Mitochondrial Bioenergetics Impaired by Hyperglycaemia in a Model of Experimental Diabetes. Int. J. Mol. Sci. 2011, 12, 8013-8026.
44. Labieniec-Watala, M.; Siewiera, K. The Impact of Seasonal Fluctuations on Rat Liver Mitochondria Response to Tested Compounds - A Comparison between Autumn and Spring. New Insight into Collecting and Interpretation of Experimental Data Originating from Different Seasons. CellBio 2013, 2, 20-30.
45. Arnold, S. The power of life-cytochrome c oxidase takes center stage in metabolic control, cell signalling and survival. Mitochondrion 2012, 12, 46-56.
46. Sjovall, F.; Morota, S.; Hansson, M.J.; Friberg, H.; Gnaiger, E.; Elmer, E. Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis. Crit. Care 2010, 14, R214.
47. Hong, S.; Bielinska, A.U.; Mecke, A.; Keszler, B.; Beals, J.L.; Shi, X.; Balogh, L.; Orr, B.G.; Baker, J.R., Jr., Banaszak Holl, M.M. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: Hole formation and the relation to transport. Bioconjug. Chem. 2004, 15, 774-782.
48. Zhang, Z.Y.; Smith, B.D. High-generation polycationic dendrimers are unusually effective at disrupting anionic vesicles: Membrane bending model. Bioconjug. Chem. 2000, 11, 805-814.
49. Klajnert, B.; Stanislawska, L.; Bryszewska, M.; Palecz, B. Interactions between PAMAM dendrimers and bovine serum albumin. Biochim. Biophys. Acta 2003, 1648, 115-126.
50. Sekowski, S.; Kazmierczak, A.; Mazur, J.; Przybyszewska, M.; Zaborski, M.; Shcharbin, D.; Gabryelak, T. The interaction between PAMAM G3.5 dendrimer, Cd2+, dendrimer-Cd2+ complexes and human serum albumin. Colloids Surf. B Biointerfaces 2009, 69, 95-98.
51. Swerdlow, R.H. Pathogenesis of Alzheimer's disease. Clin. Interv. Aging 2007, 2, 347-359.
52. Janson, J.; Laedtke, T.; Parisi, J.E.; O'Brien, P.; Petersen, R.C.; Butler, P.C. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53, 474-481.
53. Hokama, M.; Oka, S.; Leon, J.; Ninomiya, T.; Honda, H.; Sasaki, K.; Iwaki, T.; Ohara, T.; Sasaki, T.; Laferla, F.M.; et al. Altered expression of diabetes-related genes in alzheimer's disease brains: The hisayama study. Cereb. Cortex 2013, [Epub ahead of print].
54. Steen, E.; Terry, B.M.; Rivera, E.J.; Cannon, J.L.; Neely, T.R.; Tavares, R.; Xu, X.J.; Wands, J.R.; de la Monte, S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-Is this type 3 diabetes? J. Alzheimers Dis. 2005, 7, 63-80.
55. De la Monte, S.M.; Wands, J.R. Alzheimer's disease is type 3 diabetes-evidence reviewed. J. Diabetes Sci. Technol. 2008, 2, 1101-1113.
56. Xu, W.L.; von, S.E.; Qiu, C.X.; Winblad, B.; Fratiglioni, L. Uncontrolled diabetes increases the risk of Alzheimer's disease: A population-based cohort study. Diabetologia 2009, 52, 1031-1039.
57. Jolivalt, C.G.; Hurford, R.; Lee, C.A.; Dumaop, W.; Rockenstein, E.; Masliah, E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp. Neurol. 2010, 223, 422-431.
58. Jung, S.W.; Han, O.K.; Kim, S.J. Increased expression of beta amyloid precursor gene in the hippocampus of streptozotocin-induced diabetic mice with memory deficit and anxiety induction. J. Neural Transm. 2010, 117, 1411-1418.
59. Musen, G.; Lyoo, I.K.; Sparks, C.R.; Weinger, K.; Hwang, J.; Ryan, C.M.; Jimerson, D.C.; Hennen, J.; Renshaw, P.F.; Jacobson, A.M. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006, 55, 326-333.
60. Xu, W.; Caracciolo, B.; Wang, H.X.; Winblad, B.; Backman, L.; Qiu, C.; Fratiglioni, L. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010, 59, 2928-2935.
61. Zilkens, R.R.; Davis, W.A.; Spilsbury, K.; Semmens, J.B.; Bruce, D.G. Earlier age of dementia onset and shorter survival times in dementia patients with diabetes. Am. J. Epidemiol. 2013, 177, 1246-1254.
62. Vlassara, H.; Brownlee, M.; Cerami, A. Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes 1983, 32, 670-674.
63. Girones, X.; Guimera, A.; Cruz-Sanchez, C.Z.; Ortega, A.; Sasaki, N.; Makita, Z.; Lafuente, J.V.; Kalaria, R.; Cruz-Sanchez, F.F. N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic. Biol. Med. 2004, 36, 1241-1247.
64. Takeda, A.; Wakai, M.; Niwa, H.; Dei, R.; Yamamoto, M.; Li, M.; Goto, Y.; Yasuda, T.; Nakagomi, Y.; Watanabe, M.; et al. Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine]] in Alzheimer's disease brains. Acta Neuropathol. 2001, 101, 27-35.
65. Takeda, S.; Sato, N.; Uchio-Yamada, K.; Sawada, K.; Kunieda, T.; Takeuchi, D.; Kurinami, H.; Shinohara, M.; Rakugi, H.; Morishita, R. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem. Biophys. Res. Commun. 2009, 385, 193-197.
66. Sasaki, N.; Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Yoshida, T.; Fujii, N.; Koike, T.; Wakayama, I.; Yanagihara, R.; Garruto, R.; et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 1998, 153, 1149-1155.
67. Yan, S.D.; Chen, X.; Schmidt, A.M.; Brett, J.; Godman, G.; Zou, Y.S.; Scott, C.W.; Caputo, C.; Frappier, T.; Smith, M.A. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA 1994, 91, 7787-7791.
68. Dominguez, R.O.; Marschoff, E.R.; Gonzalez, S.E.; Repetto, M.G.; Serra, J.A. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res. Clin. Pract. 2012, 98, 68-74.
69. Chen, Y.; Zhou, K.; Wang, R.; Liu, Y.; Kwak, Y.D.; Ma, T.; Thompson, R.C.; Zhao, Y.; Smith, L.; Gasparini, L.; et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc. Natl. Acad. Sci. USA 2009, 106, 3907-3912.
70. Byun, K.; Bayarsaikhan, E.; Kim, D.; Kim, C.Y.; Mook-Jung, I.; Paek, S.H.; Kim, S.U.; Yamamoto, T.; Won, M.H.; Song, B.J.; et al. Induction of neuronal death by microglial AGE-albumin: Implications for Alzheimer's disease. PLoS One 2012, 7, e37917.
71. Wautier, M.P.; Chappey, O.; Corda, S.; Stern, D.M.; Schmidt, A.M.; Wautier, J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. MeTable 2001, 280, E685-E694.
72. Ko, S.Y.; Lin, Y.P.; Lin, Y.S.; Chang, S.S. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic. Biol. Med. 2010, 49, 474-480.
73. Munch, G.; Mayer, S.; Michaelis, J.; Hipkiss, A.R.; Riederer, P.; Muller, R.; Neumann, A.; Schinzel, R.; Cunningham, A.M. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim. Biophys. Acta 1997, 1360, 17-29.
74. Vitek, M.P.; Bhattacharya, K.; Glendening, J.M.; Stopa, E.; Vlassara, H.; Bucala, R.; Manogue, K.; Cerami, A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1994, 91, 4766-4770.
75. Mruthinti, S.; Sood, A.; Humphrey, C.L.; Swamy-Mruthinti, S.; Buccafusco, J.J. The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products. Neuroscience 2006, 142, 463-473.
76. Klajnert, B.; Cortijo-Arellano, M.; Cladera, J.; Bryszewska, M. Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem. Biophys. Res. Commun. 2006, 345, 21-28.
77. Kaminskas, L.M.; Kota, J.; McLeod, V.M.; Kelly, B.D.; Karellas, P.; Porter, C.J. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. J. Control. Release 2009, 140, 108-116.
78. Song, F.; Poljak, A.; Valenzuela, M.; Mayeux, R.; Smythe, G.A.; Sachdev, P.S. Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease. J. Alzheimers. Dis. 2011, 26, 365-375.
79. Kook, S.Y.; Hong, H.S.; Moon, M.; Ha, C.M.; Chang, S.; Mook-Jung, I. Aβ1-42-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca2+-calcineurin signaling. J. Neurosci. 2012, 32, 8845-8854.
80. Haataja, L.; Gurlo, T.; Huang, C.J.; Butler, P.C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr. Rev. 2008, 29, 303-316.
81. Berginc, K.; Zakelj, S.; Levstik, L.; Ursic, D.; Kristl, A. Fluorescein transport properties across artificial lipid membranes, Caco-2 cell monolayers and rat jejunum. Eur. J. Pharm. Biopharm. 2007, 66, 281-285.
82. Canis, M.; Maurer, M.H.; Kuschinsky, W.; Duembgen, L.; Duelli, R. Increased densities of monocarboxylate transporter MCT1 after chronic hyperglycemia in rat brain. Brain Res. 2009, 1257, 32-39.
83. Mason, G.F.; Petersen, K.F.; Lebon, V.; Rothman, D.L.; Shulman, G.I. Increased brain monocarboxylic acid transport and utilization in type 1 diabetes. Diabetes 2006, 55, 929-934.
84. Cura, A.J.; Carruthers, A. AMP kinase regulation of sugar transport in brain capillary endothelial cells during acute metabolic stress. Am. J. Physiol. Cell. Physiol. 2012, 303, C806-C814.
85. Newington, J.T. Reevaluating Metabolism in Alzheimer's Disease from the Perspective of the Astrocyte-Neuron Lactate Shuttle Model. J. Neurodegenr. Dis. 2013, 2013, e1-e13.
86. Parihar, M.S.; Brewer, G.J. Mitoenergetic failure in Alzheimer disease. Am. J. Physiol. Cell. Physiol. 2007, 292, C8-C23.
87. Kalousova, M.; Zima, T.; Tesar, V.; Dusilova-Sulkova, S.; Skrha, J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat. Res. 2005, 579, 37-46.
88. Marsche, G.; Frank, S.; Hrzenjak, A.; Holzer, M.; Dirnberger, S.; Wadsack, C.; Scharnagl, H.; Stojakovic, T.; Heinemann, A.; Oettl, K. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ. Res. 2009, 104, 750-757.
89. Machado-Lima, A.; Iborra, R.T.; Pinto, R.S.; Sartori, C.H.; Oliveira, E.R.; Nakandakare, E.R.; Stefano, J.T.; Giannella-Neto, D.; Correa-Giannella, M.L.; Passarelli, M. Advanced glycated albumin isolated from poorly controlled type 1 diabetes mellitus patients alters macrophage gene expression impairing ABCA-1-mediated reverse cholesterol transport. Diabetes Metab. Res. Rev. 2013, 29, 66-76.
90. Vlassopoulos, A.; Lean, M.E.; Combet, E. Role of oxidative stress in physiological albumin glycation: A neglected interaction. Free Radic. Biol. Med. 2013, 60C, 318-324.
91. Guerin-Dubourg, A.; Catan, A.; Bourdon, E.; Rondeau, P. Structural modifications of human albumin in diabetes. Diabetes MeTable 2012, 38, 171-178.
92. Klajnert, B.; Bryszewska, M. Fluorescence studies on PAMAM dendrimers interactions with bovine serum albumin. Bioelectrochemistry 2002, 55, 33-35.
93. Liu, Q.; Tian, J.; Zhang, C.; Yang, H.; Liu, Y.; Qin, W.; Liu, Z. Cationic poly(amidoamine) dendrimers as additives for capillary electroseparation and detection of proteins. Electrophoresis 2011, 32, 1302-1308.
94. Shcharbin, D.; Klajnert, B.; Bryszewska, M. The effect of PAMAM dendrimers on human and bovine serum albumin at different pH and NaCl concentrations. J. Biomater. Sci. Polym. Ed. 2005, 16, 1081-1093.
95. Quinlan, G.J.; Martin, G.S.; Evans, T.W. Albumin: Biochemical properties and therapeutic potential. Hepatology 2005, 41, 1211-1219.
96. Sekowski, S.; Buczkowski, A.; Palecz, B.; Gabryelak, T. Interaction of polyamidoamine (PAMAM) succinamic acid dendrimers generation 4 with human serum albumin. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2011, 81, 706-710.
97. Froehlich, E.; Mandeville, J.S.; Jennings, C.J.; Sedaghat-Herati, R.; Tajmir-Riahi, H.A. Dendrimers bind human serum albumin. J. Phys. Chem. B 2009, 113, 6986-6993.
98. Shukla, D.; Schneider, C.P.; Trout, B.L. Effects of PAMAM Dendrimer Salt Solutions on Protein Stability. J. Phys. Chem. Lett. 2011, 2, 1782-1788.
99. Shcharbin, D.; Janicka, M.; Wasiak, M.; Palecz, B.; Przybyszewska, M.; Zaborski, M.; Bryszewska, M. Serum albumins have five sites for binding of cationic dendrimers. Biochim. Biophys. Acta 2007, 1774, 946-951.
100. Giri, J.; Diallo, M.S.; Simpson, A.J.; Liu, Y.; Goddard, W.A.; Kumar, R.; Woods, G.C. Interactions of poly(amidoamine) dendrimers with human serum albumin: Binding constants and mechanisms. ACS Nano 2011, 5, 3456-3468.
101. Foster, J.F. Binding properties of albumin. In Albumin Structure, Function and Uses; Rosenoer, V.M., Oratz, M., Rothschield, M.A., Eds.; Pergamon Press: Oxford, UK, 1977; pp. 53-84.
102. Oncley, J.L. Dielectric behavior and atomic structure of serum albumin. Biophys. Chem. 2003, 100, 151-158.
103. Kragh-Hansen, U. Structure and ligand binding properties of human serum albumin. Dan. Med. Bull. 1990, 37, 57-84.
104. Sudlow, G.; Birkett, D.J.; Wade, D.N. The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 1975, 11, 824-832.
105. Geisow, M.J.; Beaven, G.H. Physical and binding properties of large fragments of human serum albumin. Biochem. J. 1977, 163, 477-484.
106. Mandeville, J.S.; Tajmir-Riahi, H.A. Complexes of dendrimers with bovine serum albumin. Biomacromolecules. 2010, 11, 465-472.
107. Ottaviani, M.F.; Jockusch, S.; Turro, N.J.; Tomalia, D.A.; Barbon, A. Interactions of dendrimers with selected amino acids and proteins studied by continuous wave EPR and Fourier transform EPR. Langmuir 2004, 20, 10238-10245.
108. Klajnert, B.; Pikala, S.; Bryszewska, M. Haemolytic activity of polyamidoamine dendrimers and the protective role of human serum albumin. Proc. R. Soc. A Math. Phys. Eng. Sci. 2010, 466, 1527-1534.
109. Lahousen, T.; Hegenbarth, K.; Ille, R.; Lipp, R.W.; Krause, R.; Little, R.R.; Schnedl, W.J. Determination of glycated hemoglobin in patients with advanced liver disease. World J. Gastroenterol. 2004, 10, 2284-2286.
110. Shin, J.J.; Gorden, P.; Libutti, S.K. Insulinoma: Pathophysiology, localization and management. Future. Oncol. 2010, 6, 229-237.
111. Hare, M.J.; Shaw, J.E.; Zimmet, P.Z. Current controversies in the use of haemoglobin A1c. J. Intern. Med. 2012, 271, 227-236.
112. Domanski, D.M.; Klajnert, B.; Bryszewska, M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 2004, 63, 189-191.
113. Han, M.H.; Chen, J.; Wang, J.; Chen, S.L.; Wang, X.T. Blood compatibility of polyamidoamine dendrimers and erythrocyte protection. J. Biomed. Nanotechnol. 2010, 6, 82-92.